Reata Pharmaceuticals Inc. (NASDAQ:RETA) and Acasti Pharma Inc. (NASDAQ:ACST) compete against each other in the Biotechnology sector. We will contrast them and contrast their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reata Pharmaceuticals Inc.	52.35M	53.13	80.55M	-2.64	0.00
Acasti Pharma Inc.	N/A	0.00	N/A	-1.22	0.00

Demonstrates Reata Pharmaceuticals Inc. and Acasti Pharma Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

	Net Margins	Return on Equity	Return on Assets
Reata Pharmaceuticals Inc.	-153.87%	0%	0%
Acasti Pharma Inc.	0.00%	0%	0%

Institutional and Insider Ownership

Reata Pharmaceuticals Inc. and Acasti Pharma Inc. has shares owned by institutional investors as follows: 68.6% and 3.77%. 4.1% are Reata Pharmaceuticals Inc.’s share owned by insiders. Competitively, insiders own roughly 8.49% of Acasti Pharma Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Reata Pharmaceuticals Inc.	13.58%	27.6%	57.18%	19.28%	331.86%	81.44%
Acasti Pharma Inc.	0%	0.93%	56.52%	118.84%	9.09%	29.82%

For the past year Reata Pharmaceuticals Inc. has stronger performance than Acasti Pharma Inc.

Summary

Reata Pharmaceuticals Inc. beats on 4 of the 7 factors Acasti Pharma Inc.

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates for patients with rare and life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. Its lead product candidates include Bardoxolone methyl, which is in Phase III clinical trial for the treatment of pulmonary arterial hypertension and associated with connective tissue disease, as well as in Phase II clinical trial for the treatment of pulmonary hypertension due to interstitial lung disease and pulmonary arterial hypertension; and Omaveloxolone that is in Phase II clinical trial for the treatment of FriedreichÂ’s ataxia, mitochondrial myopathies, and metastatic melanoma. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas.

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia. Acasti Pharma Inc. was incorporated in 2002 and is based in Laval, Canada.